Consolidated statements of cash flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (76,677)	$ (37,560)	$ (42,590)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,151	3,084	2,569
Amortization of discount on debt	574	774	54
Stock-based compensation	25,424	11,058	3,156
Allowance for credit losses	3,474	1,594	988
Accretion on discount to marketable securities			(69)
Change in fair value of financial instrument		(4,413)
Changes in operating assets and liabilities:
Accounts receivable	(17,279)	(9,305)	(6,297)
Prepaid expenses	(2,413)	(2,704)	(1,786)
Deferred commissions	(3,525)	(2,396)	(903)
Accounts payable	2,137	1,907	(1,582)
Accrued and other current liabilities	20,437	9,610	8,164
Deferred revenue	1,397	1,822	(1,673)
Net cash used in operating activities	(40,300)	(26,529)	(39,969)
Cash flows from investing activities:
Cash paid for acquisition	(81,067)
Purchase of marketable securities	(107,006)
Purchase of property and equipment	(3,304)	(1,964)	(5,579)
Maturity of marketable securities	4,500		23,450
Net cash (used in) provided by investing activities	(186,877)	(1,964)	17,871
Cash flows from financing activities:
Payment of debt issuance costs	(10,037)
Purchase of capped calls	(35,570)
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs		171,129
Proceeds from issuance of common stock upon secondary offering, net of underwriting discounts and commissions and other offerings costs		65,112
Payment of Series F dividends		(12,814)
Proceeds from exercise of stock options and warrants	5,881	3,279	901
Proceeds from debt	345,000	41,861	18,500
Repayment of debt		(28,617)	(2,050)
Net cash provided by financing activities	305,274	239,950	17,351
Net change in cash and cash equivalents and restricted cash	78,097	211,457	(4,747)
Cash and cash equivalents and restricted cash, beginning of period	220,607	9,150	13,897
Cash and cash equivalents and restricted cash, end of period	298,704	220,607	9,150
Supplemental cash flow information:
Cash paid for interest		2,285	1,626
Noncash investing and financing activities:
Fair value of shares issued as consideration for acquisition	2,003
Conversion of convertible preferred stock into common stock upon initial public offering		211,902
Conversion of convertible debt into common stock upon initial public offering		50,173
Reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheet to the amounts shown in the statements of cash flows above:
Cash and cash equivalents	297,561	219,447	7,795
Restricted cash	1,143	1,160	1,355
Cash and cash equivalents and restricted cash, end of period	$ 298,704	$ 220,607	$ 9,150